Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07042516Phase 2Recruiting

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

Role: lead

NCT02475447Phase 2Completed

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Role: lead

NCT01100684Phase 3Completed

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Role: lead

NCT00443040Phase 2Terminated

Asimadoline for the Treatment of Post-Operative Ileus

Role: lead

NCT00454688Phase 2Completed

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

Role: lead

NCT01380561Phase 1Completed

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

Role: lead

All 6 trials loaded